BeOne Medicines AG (BVMF:B1ME34)

Market Cap	180.45B +31.3%
Revenue (ttm)	29.43B +40.2%
Net Income	1.58B
EPS	13.60
Shares Out	n/a
PE Ratio	114.18
Forward PE	55.07
Dividend	n/a
Ex-Dividend Date	n/a

Volume	300
Average Volume	177
Open	67.22
Previous Close	n/a
Day's Range	67.22 - 67.22
52-Week Range	51.48 - 72.73
Beta	n/a
RSI	52.11
Earnings Date	Feb 26, 2026

About BeOne Medicines AG

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Employees: 11,000
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: B1ME34

Financial Performance

Financial numbers in USD